DoD Gulf War Illness, Therapeutic/Biomarker Trial Award | W81XWH 21 GWIRP TBTA

Opportunity Information: Apply for W81XWH 21 GWIRP TBTA

The DoD Gulf War Illness, Therapeutic/Biomarker Trial Award (FY21 GWIRP TBTA; Funding Opportunity Number W81XWH-21-GWIRP-TBTA) is a Department of Defense Gulf War Illness Research Program funding mechanism meant to push Gulf War Illness (GWI) treatment research into large, decisive human studies. It is specifically aimed at the "Confirmation" stage of the program's research pipeline, meaning the government is looking for pivotal clinical trials (typically phase 2b through phase 3) that can credibly change clinical practice and materially improve how GWI is treated. The expectation is that the proposed approach is not just incremental, but fundamentally better than treatments already approved or currently moving through clinical development.

A central feature of this opportunity is the required integration of biomarkers into the clinical trial itself. Applicants must build their trial around objective biomarkers that either (1) measure the biological effect of the investigational therapy (pharmacodynamic or mechanism-linked markers) or (2) predict who is likely to benefit, including cohort-selective biomarkers that can identify a responsive subgroup of Gulf War Veterans. In contrast, biomarker work that is disconnected from therapy development, such as markers intended only for diagnosis, prognosis, or tracking disease progression without a clear role in therapeutic decision-making, is explicitly not supported under this award.

Because this is a treatment-focused mechanism, every application must address the FY21 GWIRP Overarching Challenge of "Treatments." Applicants are encouraged to align with the broader Gulf War Illness Landscape and GWIRP mission, and they may also address other GWIRP challenges if they clearly justify why those challenges matter for the proposed therapeutic trial. The award is designed for teams that can realistically execute complex, multi-site, regulated clinical research, and the Principal Investigator is expected to have strong experience leading large-scale projects or to include a committed clinical investigator collaborator who can demonstrate the capability to run the trial successfully.

Only projects that meet the program's definition of a clinical trial are eligible for funding. In this context, a clinical trial means human subjects are prospectively assigned to one or more interventions (including placebo or controls) to evaluate effects on biomedical or behavioral health outcomes. Funded studies must meet human subjects protections and transparency requirements, including posting the IRB-approved informed consent form on a publicly available federal website, consistent with 32 CFR 219 (2 CFR 219). The opportunity also clarifies what counts as clinical research versus excluded activities; for example, purely in vitro studies on de-identified human specimens that cannot be linked to living individuals fall outside the patient-oriented category, and studies that qualify for IRB Exemption 4 (existing de-identified data/specimens, publicly available) are not considered CDMRP-defined clinical research for these purposes. Applicants who want to do preclinical work are steered to other GWIRP announcements instead.

For trials that require FDA oversight, the program sets a high "readiness" bar at the time of application. Applicants must show they have access to regulatory-compliant clinical reagents (the therapeutic or device), access to an appropriate Gulf War Veteran population, and credible recruitment projections. They also must submit an Investigational New Drug (IND) application or an Investigational Device Exemption (IDE) application to the FDA by the application deadline when required, and the submission must match the exact product/device and indication being tested. If the team believes an IND or IDE is not required, they must provide documentation from the IRB of record or the FDA supporting that conclusion. The government also notes it can withdraw funding if a necessary IND/IDE (or international regulatory submission) was not filed by the deadline, underscoring that these awards are intended for trials that are ready to launch rather than early planning efforts.

The program encourages applicants to leverage existing GWIRP infrastructure through two optional collaboration pathways, each associated with a higher allowable direct-cost cap if used. The Biorepository Contribution Option encourages investigators to contribute biospecimens and/or data to the established GWI biorepository network known as BBRAIN (Boston Biorepository, Recruitment, and Integrative Network for GWI). This option is meant to increase the long-term value of funded trials by ensuring specimens and data can support future research. Separately, the Clinical Consortium Collaboration Option encourages applicants to use the established Gulf War Illness Clinical Trials and Interventions Consortium (GWICTIC) infrastructure, such as recruitment networks, existing protocols, common data elements, and data management procedures. This consortium option requires a formal letter of collaboration from GWICTIC that spells out what services or infrastructure will be shared and how that creates value for the government. Importantly, applicants choosing the consortium collaboration path cannot also apply under the biorepository contribution option, because consortium projects must follow GWICTIC policies for data and biospecimens.

The announcement also spells out multiple operational requirements that signal what reviewers will consider essential for a successful, credible pivotal trial. Preliminary data relevant to the proposed GWI trial is required, and the study is expected to begin quickly: within 12 months of award, or within 18 months for FDA-regulated studies. Applications must include a strong recruitment and retention plan and demonstrate real access to a Gulf War Veteran population sufficient to achieve statistically meaningful outcomes; once funded, teams will work with USAMRAA to establish recruitment milestones, and continued funding depends on satisfactory progress against those milestones. Applicants must show access to the therapeutic or device for the full study duration, with documentation of quality and stability consistent with applicable FDA manufacturing expectations (for example, GMP or Quality System Regulation, depending on product type). If the project is FDA-regulated, the team should demonstrate prior experience interacting with the FDA, including submission history.

On the design and oversight side, the application must include a clear statistical analysis plan, appropriate statistical expertise, and a power analysis tied to sample size projections that can actually answer the study questions. It must also include a safety management plan for pharmacovigilance as applicable, a clinical monitoring plan addressing Good Clinical Practice compliance, and a data management plan with an appropriate database to protect integrity and security of trial data. For FDA-regulated studies, the database must be 21 CFR 11-compliant and use appropriate data standards. The program also expects a dedicated study coordinator function to shepherd the protocol through IRB and other regulatory processes, coordinate multi-site operations, and manage participant accrual. Finally, applicants must provide a Transition Plan describing how the product will move to the next phase of testing and/or be delivered to Veterans with GWI if results are positive, including the likely funding and resources needed beyond the award. Strong institutional support is expected, including (when relevant) a commitment to act as the FDA regulatory sponsor and fulfill sponsor responsibilities under 21 CFR 312, Subpart D. Funded trials must also be registered on ClinicalTrials.gov prior to study initiation.

The opportunity clearly identifies topics it will not support. In particular, it will not fund studies that treat psychiatric disease or psychological stress as the primary cause of GWI, or that implement care guidelines that heavily emphasize psychiatric pathologies or psychiatric remedies. It also excludes applications focused on amyotrophic lateral sclerosis (ALS) as the central research topic, although trials focused on GWI symptomatology may include Gulf War Veterans with ALS if ALS is part of the study's GWI case definition. Applicants who want to pursue ALS as the primary focus are directed to the separate CDMRP ALS Research Program.

Awards under this announcement are made as assistance agreements, meaning they will be issued as either a grant or a cooperative agreement depending on the anticipated level of DoD involvement during performance. If the government expects no substantial involvement, it uses a grant; if substantial involvement is expected (such as collaboration or participation in the work), it uses a cooperative agreement, and the specific involvement is described in the award. The administering agency is the Department of Defense, Department of the Army, through USAMRAA, and eligibility is broadly unrestricted across organization types (subject to any clarifications in the full announcement).

On funding, the anticipated maximum direct costs for the entire project period are capped at $5,000,000 for standard applications, $5,020,000 if using the Biorepository Contribution Option, and $5,500,000 if using the Clinical Consortium Collaboration Option. The announcement notes that budgets must be appropriate for the phase and scale of the proposed trial rather than inflated beyond need. Programmatically, CDMRP expected to allocate about $8.0 million total to fund roughly one award under this mechanism, so this is a highly competitive, single-award opportunity. For the FY21 cycle described, the posting date was March 11, 2021, the original closing date was August 19, 2021, and awards were expected no later than September 30, 2022. Funds were anticipated to be FY21 appropriations with an expiration for use on September 30, 2027, which matters for scheduling, obligation timelines, and the practical window for spending.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Gulf War Illness, Therapeutic/Biomarker Trial Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Mar 11, 2021.
• Applicants must submit their applications by Aug 19, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 1 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 GWIRP TBTA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: